Evolus (EOLS) Revenue Growth (1y) (2020 - 2026)
Evolus (EOLS) Revenue Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -0.81% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -0.24% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 0.07% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | -1.92% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 4.88% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 39.49% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 10.23% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn | 21.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.18% |
| Mar 31, 2026 | 6.74% |
| Dec 31, 2025 | 14.38% |
| Sep 30, 2025 | 12.90% |
| Jun 30, 2025 | 3.70% |
| Mar 31, 2025 | 15.49% |
| Dec 31, 2024 | 29.42% |
| Sep 30, 2024 | 22.12% |
| Jun 30, 2024 | 35.59% |
| Mar 31, 2024 | 42.21% |
| Dec 31, 2023 | 39.76% |
| Sep 30, 2023 | 47.55% |
| Jun 30, 2023 | 32.78% |
| Mar 31, 2023 | 23.04% |
| Dec 31, 2022 | 25.94% |
| Sep 30, 2022 | 27.07% |
| Jun 30, 2022 | 42.40% |
| Mar 31, 2022 | 177.00% |
| Dec 31, 2021 | 68.43% |
| Sep 30, 2021 | 51.05% |